Pancreatic Cancer Research

ResearcherShandong UniversityNo recent work listed

Zequn Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8055-6994; OpenAlex author ID A5065893033. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 3

  1. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. Co-author DOI 10.1002/advs.202201931↗
  2. Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer. Co-author DOI 10.3892/ijo.2020.5053↗
  3. Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDA… Co-author DOI 10.1007/s13277-015-4353-7↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Penghong Song · 2 shared papers, 2020–2022 · strength 0.25
  2. Suchen Bian · 1 shared paper, 2022 · strength 0.14
  3. Hangxiang Wang · 1 shared paper, 2022 · strength 0.14
  4. Shusen Zheng · 1 shared paper, 2022 · strength 0.14
  5. Huijie Gao · 1 shared paper, 2016 · strength 0.06
  6. Weibo Niu · 1 shared paper, 2016 · strength 0.06
  7. Jun Niu · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.